DELFI Diagnostics develops AI-powered liquid biopsy tests using fragmentomics and genome-wide analysis of cell-free DNA to support early cancer detection and treatment monitoring.
Jobs
See all jobs for DELFI Diagnostics here.
Funding
All fundraising announcements are based on public sources. Please contact Cosign if you believe there are any discrepancies, or claim the profile to edit.
Series B
$225M
Series A
$100M
Seed